Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.55 |
| ▸ | FNTB | P49356 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | C3AR1 | Q16581 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13826436 | 0.86 | C3AR1 (0.56) | FNTAFNTBALDH1A1KDM4EC3AR1 | |
| SCHEMBL2606193 | 0.85 | FNTA (0.58) | FNTAFNTBALDH1A1KDM4EMEN1 | |
| SCHEMBL22875382 | 0.84 | L3MBTL1 (0.66) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL22493291 | 0.83 | FNTA (0.58) | FNTAFNTBALDH1A1KDM4EC3AR1 | |
| SCHEMBL16002962 | 0.82 | FNTA (0.55) | FNTAFNTBALDH1A1KDM4EC3AR1 | |
| SCHEMBL18705020 | 0.82 | FNTA (0.63) | FNTAFNTBALDH1A1KDM4EMEN1 | |
| SCHEMBL25676008 | 0.81 | GRIN2B (0.56) | ALDH1A1 | |
| SCHEMBL21835176 | 0.81 | FNTA (0.65) | FNTAFNTBALDH1A1KDM4EMEN1 | |
| SCHEMBL30522511 | 0.81 | FNTA (0.65) | FNTAFNTBALDH1A1KDM4EMEN1 | |
| SCHEMBL18389960 | 0.80 | HSD11B1 (0.69) | FNTAFNTBALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | FNTA 1343/4885FNTB 1272/4885ALDH1A1 361/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | FNTA 1282/4885FNTB 1896/4885ALDH1A1 285/4885 |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | FNTA 904/4885FNTB 477/4885ALDH1A1 3028/4885 |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | FNTA 850/4885FNTB 449/4885ALDH1A1 3055/4885 |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | FNTA 850/4885FNTB 449/4885ALDH1A1 3055/4885 |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | FNTA 850/4885FNTB 449/4885ALDH1A1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.